The Impact of Wild-Type Reversion on Transmitted Resistance Surveillance

Bennett D.E. , Myatt M. , Bertagnolio S. , Sutherland D. , Gilks C F. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2: 25–36.

Hamers R.L. , Oyomopito R. , Kityo C. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance–HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2012; 41: 43–54.

Cong M.E. , Heneine W. , Garcia-Lerma J.G. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81: 3037–3041.

Gonzalez L.M. , Brindeiro R.M. , Aguiar R.S. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004; 48: 3552–3555.

Paredes R. , Sagar M. , Marconi V.C. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 2009; 83: 2038–2043.

Zimmer J.M. , Roman F. , Lambert C. Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation. J Acquir Immune Defic Syndr 2008; 48: 255–262.

Castro H. , Pillay D. , Cane P. Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis 2013; 208: 1459–1463.

Kiertiburanakul S. , Chaiwarith R. , Sirivichayakul S. Comparisons of primary HIV-1 drug resistance between recent and chronic HIV-1 infection within a sub-regional cohort of Asian patients. PLoS ONE 2013; 8: e62057.

Jain V. , Sucupira M.C. , Bacchetti P. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011; 203: 1174–1181.

Hecht F.M. , Busch M.P. , Rawal B. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002; 16: 1119–1129.

Kallas E.G. , Bassichetto K.C. , Oliveira S.M. Establishment of the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) strategy in the city of Sao Paulo, Brazil. Braz J Infect Dis 2004; 8: 399–406.

Metzner K.J. , Rauch P. , Braun P. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients. J Clin Virol 2011; 50: 156–161.

Shafer R.W. , Rhee S.Y. , Pillay D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21: 215–223.

Bennett D.E. , Camacho R.J. , Otelea D. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.

Megens S. , Laethem K V. HIV-1 genetic variation and drug resistance development. Expert Rev Anti Infect Ther 2013; 11: 1159–1178.